In head and neck cancer models, targeting SPP1+ macrophage derived cytokines, particularly TNF-α and IL-1β with the inhibitor significantly impaired tumor cell proliferation and migration in vitro and reduced tumor growth in vivo. This evidence concerns the gene IL1B and neoplasm.